NASDAQ:HROW

Imprimis Pharmaceuticals Stock Predictions

Healthcare > Drug Manufacturers - Specialty & Generic

Buy HROW

*Your capital is at risk

$42.78

+0.370 (+0.87%)

At Close: Jun 23, 2026

Currently predicting for Wed, 24 Jun 2026

HROW Live board

Community Bull/Bear

Target Next close

Join the HROW prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

HROW Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For HROW

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

HROW Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT IMPRIMIS PHARMACEUTICALS

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharma...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
IDYA $28.98	20.46%	Jun 12
DHI $146.71	6.39%	Jun 10
E ETD $20.67	4.79%	Jun 05
EAT $140.46	16.94%	Jun 05
OSW $24.00	17.08%	Jun 04

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by